The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

Status Recruiting

Clinical Trial Summary

To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival.

Clinical Trial Description

Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival. ;

Study Design

Related Conditions & MeSH terms

Radiation Toxicity

Clinical Trial Details

NCT number	NCT06311968
Study type	Interventional
Source	Shanghai Proton and Heavy Ion Center
Contact	Jing Li
Phone	86-21-38296678
Email	jing.li@sphic.org.cn
Status	Recruiting
Phase	Phase 2
Start date	April 1, 2024
Completion date	February 28, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04059809` - Photobiomodulation for Breast Cancer Radiodermatitis	Phase 2/Phase 3
Recruiting	`NCT03876860` - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis	N/A
Completed	`NCT02058550` - Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy	Phase 1
Completed	`NCT01434290` - Radiation Therapy in Treating Patients With Prostate Cancer	Phase 2
Completed	`NCT01399372` - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma	Phase 2
Active, not recruiting	`NCT00087815` - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain	N/A
Completed	`NCT01407770` - Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
Completed	`NCT00003313` - Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer	Phase 3
Completed	`NCT03783364` - Pre- or Postoperative Accelerated Radiotherapy	N/A
Enrolling by invitation	`NCT04305613` - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Recruiting	`NCT06036706` - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:	N/A
Withdrawn	`NCT04593914` - A Novel Skin Barrier Protectant for Acute Radiodermatitis	N/A
Recruiting	`NCT04110223` - Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
Active, not recruiting	`NCT02259218` - Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Recruiting	`NCT06073509` - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Withdrawn	`NCT02017925` - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation	N/A
Completed	`NCT01170299` - Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer	N/A
Completed	`NCT00974168` - Spinal Cord Compression Re-Treat Study	Phase 2
Completed	`NCT00008398` - Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer	Phase 3
Enrolling by invitation	`NCT04047823` - Temperature and Injury in Radiotherapy Radiation Skin Injury